Xceleron to acquire an Accelerator Mass Spectrometry instrument under agreement with GlaxoSmithKline

XCELERON, a leader in the field of ultra-sensitive bioanalytical studies supporting clinical research, today announced that it has signed a second Master Service Agreement with GlaxoSmithKline. Under the terms of this agreement, Xceleron will provide analytical support to GlaxoSmithKline and its affiliated research organizations. As part of the deal, Xceleron will increase capacity through the acquisition of an Accelerator Mass Spectrometry (AMS) instrument.

Clinical studies supported by AMS allow early investigations of the human relevancy of new drugs and novel investigational paradigms greatly enhancing the drug discovery and development process. This second agreement is focused on the rapid analyses and data turnaround for early clinical studies performed by GlaxoSmithKline or its academic and various innovator collaborators. It is complementary to an existing agreement between the two companies in which a bioanalytical service is provided to support clinical studies for regulatory submission.

Michael Butler, Ph.D., Chief Executive Officer at Xceleron observed, “We’re just pleased that GlaxoSmithKline recognizes the value of AMS, and Xceleron’s expertise with this ultra-sensitive methodology. We’re now well-positioned to strengthen an already productive collaboration.”